Skip to main content

LCD L36658: Proton Beam Therapy

LCD L36658, Proton Beam Therapy, is the Local Coverage Determination that CGS Administrators, LLC applies to claims from 2 states (KY, OH), effective 2026-10-08 and first in force 2016-10-24. The policy text runs 1,765 words, and its billing and coding article A55315 lists 430 ICD-10-CM codes that support medical necessity for 4 procedure codes. 1 other contractor version share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 430 covered ICD-10-CM codes: 132 fewer codes than L35075 (Wellpoint Federal, 562 codes, revised 2026-04-01).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
CGS Administrators, LLC
States and territories
2
KY OH
Revision effective
2026-10-08
Original effective
2016-10-24
Policy text
1,765 words
Covered ICD-10 codes (articles)
430

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L36658
ContractContractorTypeStates
15102CGS Administrators, LLCMAC - Part BKY
15202CGS Administrators, LLCMAC - Part BOH
15101CGS Administrators, LLCMAC - Part AKY
15201CGS Administrators, LLCMAC - Part AOH

Billing and coding article A55315: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A55315 (Billing and Coding: Proton Beam Therapy) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A55315: Billing and Coding: Proton Beam Therapy (Billing and Coding, effective 2026-11-05)

Covered ICD-10-CM codes
430
2 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
4
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A55315
ICD-10-CMDescription (FY2027)
C00.0Malignant neoplasm of external upper lip
C00.1Malignant neoplasm of external lower lip
C00.3Malignant neoplasm of upper lip, inner aspect
C00.4Malignant neoplasm of lower lip, inner aspect
C00.6Malignant neoplasm of commissure of lip, unspecified
C00.8Malignant neoplasm of overlapping sites of lip
C01Malignant neoplasm of base of tongue
C02.0Malignant neoplasm of dorsal surface of tongue
C02.1Malignant neoplasm of border of tongue
C02.2Malignant neoplasm of ventral surface of tongue
C02.3Malignant neoplasm of anterior two-thirds of tongue, part unspecified
C02.4Malignant neoplasm of lingual tonsil
C02.8Malignant neoplasm of overlapping sites of tongue
C03.0Malignant neoplasm of upper gum
C03.1Malignant neoplasm of lower gum
C04.0Malignant neoplasm of anterior floor of mouth
C04.1Malignant neoplasm of lateral floor of mouth
C04.8Malignant neoplasm of overlapping sites of floor of mouth
C04.9Malignant neoplasm of floor of mouth, unspecified
C05.0Malignant neoplasm of hard palate
C05.1Malignant neoplasm of soft palate
C05.2Malignant neoplasm of uvula
C05.8Malignant neoplasm of overlapping sites of palate
C06.0Malignant neoplasm of cheek mucosa

Procedure codes: 77520, 77522, 77523, 77525.

Coverage indications, limitations and medical necessity

In conventional external beam radiation therapy (EBRT), the targeted tissue usually receives 95-100% of the intended dose. A major limitation of EBRT is that in some situations, because critical normal tissues cannot be completely protected from the radiation, a curative dose cannot be used.

Proton beam radiotherapy is a form of conformal external beam radiation treatment. Protons are positively charged atomic particles and have similar biological effects as conventional x-ray beams, but have very different energy disposition or physics profiles. Conventional x-ray beams give off the most energy a short distance below the skin surface (entrance dose) and continue to deposit some dose throughout the path of the beam even beyond the target (exit dose). Conventional EBRT delivers radiation to a more broad range of diseased and normal tissues with targeted tissue receiving approximately 95-100% of the intended dose but a larger volume of normal/unintended tissue receiving a significantly higher dose of radiation that is approximately 20-60% of the dose. In short, there is a higher integral dose to the normal tissue with conventional external beam therapy.

In contrast, proton particles deposit a smaller amount of radiation energy as they enter the body (lower entrance dose), culminating in an intensity dose peak, also called the Bragg Peak. There is no further energy deposition beyond the Bragg peak (no exit dose). The depth of the peak can be controlled by the amount of the proton's energy. While the unaltered Bragg Peak is measured in millimeters, it can be spread out to encompass whole or partial volumes of a tumor. Like other conformal radiation modalities, proton beams can be precisely delivered to the tumor volume without harming surrounding healthy tissue or critical organs. Proton beams typically deposit less radiation in normal non-targeted tissues than conventional radiation therapy and have been used to escalate the radiation dose to diseased tissues while minimizing damage to adjacent normal tissues. Proton beam therapy will typically have a significantly lower integral dose (dose to the whole body of the patient) compared to conventional x-ray therapy. Intensity-modulated radiation therapy (IMRT), gives integral radiation dose to normal tissues compared to proton beam therapy. Due to reduction in integral dose with protons the most important benefits can be expected for pediatric patients.

Proton beam therapy is of particular value in those tumors located close to vital organs (or organs at risk) where a small local overdose can cause fatal complications such as tumors close to the spinal cord. Irregular shaped lesions near critical structures are well suited for protons. In general, proton beam radiotherapy is not indicated for cancers that are widely disseminated, such as leukemias or malignancies with hematogenous metastases or as a short term palliative procedure. Proton beam therapy is also not indicated in the treatment of very radiosensitive tumors such as lymphomas or germ cell neoplasms. The intent of treatment should be curative. If proton beam radiotherapy is used for a patient with metastatic disease, evidence should be provided to justify the expectation of a long-term benefit (> 2y), as well as evidence of a dosimetric advantage for proton beam radiotherapy over other forms of radiation therapy. Due to the reduction in integral dose with protons, the most important benefits can be expected for pediatric patients. In adults, proton beam therapy should be reserved to treat patients that have clinically apparent disease (by exam or medical imaging).

Protons provide a dosimetric advantage compared to x-rays for many tumor treatment sites. In general, x-rays give 1.5 to 3 times more integral dose outside the target volume than protons, primarily in the low and medium dose range. There is no benefit to irradiating normal tissues outside of the intended treatment volume, and treatment to larger volumes of normal tissues is associated with increased toxicity, including an increased risk of second malignancies.

Stereotactic techniques are sometimes used with proton beam therapy especially for skull based, uveal tract tumors and others.

The proton beam therapy system must be FDA approved.

Indications:

Proton beam therapy will be considered medically reasonable and necessary for the following conditions:

Group 1

• Unresectable benign or malignant central nervous system tumors to include but not limited to primary and variant forms of astrocytoma, glioblastoma, medulloblastoma, acoustic neuroma, craniopharyngioma, benign and atypical meningiomas, pineal gland tumors, and arteriovenous malformations

• Intraocular melanomas

• Pituitary neoplasms

• Chordomas and chondrosarcomas

• Advanced staged and unresectable malignant lesions of the head and neck

• Malignant lesions of the Para nasal sinus, and other accessory sinuses

• Unresectable retroperitoneal sarcoma

• Solid tumors in children

In addition to the criteria in Group I, Proton Beam Therapy indications must demonstrate that:

• The Dose Volume Histogram (DVH) one or more critical structures or organs protected by the use of Proton Beam Therapy;

• The dose to control or treat the tumor cannot be delivered without exceeding the tolerance of the normal tissue;

• There is documented clinical rationale that doses generally thought to be above the level otherwise attainable with other radiation methods might improve control rates; or

• There is documented clinical rationale that higher levels of precision associated with Proton Beam Therapy compared to other radiation treatments are clinically necessary.

For the treatment of primary lesions, the intent of treatment must be curative. For the treatment of metastatic lesions, there must be

• the expectation of a long-term benefit (greater than 2 year of life expectancy) that could not have been attained with conventional therapy, or

• the expectation of a complete eradication or improved duration of control of the metastatic lesion that could not have been safely accomplished with conventional therapy, as evidenced by a dosimetric advantage for proton beam radiotherapy over other forms of radiation therapy.

• The patient’s record demonstrates why Proton beam radiotherapy is considered the treatment of choice for the individual patient. Specifically, the record must address the lower risk to normal tissue, the lower risk of disease recurrence, and the advantages of the treatment over IMRT or 3- dimensional conformal radiation. Dosimetric evidence of reduced normal tissue toxicity and/or improved tumor control must be maintained.

If the above provisions are met and the patient is treated in a protocol that is designed for evidence development and for future publication, it is expected that future published data will support an outcome advantage for Medicare patients for continued coverage of the specific diagnosis. The protocol in and by itself does not constitute criteria for coverage. The presence of an Institutional Review Board (IRB) review when appropriate and patient informed consent are also expected.

Group 2

This section defines conditions that are still under investigation and would be covered when part of a clinical trial, registry or both. (See details in coding section)

• Unresectable lung cancers and upper abdominal/peri-diaphragmatic cancers

• Advanced stage, unresectable pelvic tumors including those with peri-aortic nodes or malignant lesions of the cervix

• Left breast tumors

• Unresectable pancreatic and adrenal tumors

• Skin cancer with macroscopic perineural/cranial nerve invasion of skull base

• Unresectable Malignant lesions of the liver, biliary tract, anal canal and rectum

• Prostate Cancer, Non-Metastatic.

Prostate Cancer

There is as yet no good comparative data to determine whether or not Proton Beam Therapy for prostate cancer is superior, inferior, or equivalent to external beam radiation, IMRT, or brachytherapy in terms of safety or efficacy.

The prostate cancer should be locally contained and not be an advanced prostate cancer (i.e. T3 or T4 where the tumor has spread through the capsule or has invaded seminal vesicles or other structures) and not any N disease (i.e. no spread to lymph nodes or there has been spread to the pelvic lymph nodes). Note: spread into pelvic lymph nodes is considered metastatic disease.

Coverage and payments of Proton Beam Therapy for prostate cancer will require:

• Physician documentation of patient selection criteria (stage and other factors as represented in the NCCN guidelines); and

• Documentation and verification that the patient was informed of the range of therapy choices, including risks and benefits.

Other factors considered favorable for coverage include enrollment of the patient in an appropriate clinical registry for planned assessment and publication, clinical trials.

In addition to the criteria in Group II, Proton Beam Therapy indication must demonstrate that:

• T and N Staging must be documented by CT or MRI scan findings;

• The Dose Volume Histogram (DVH) illustrates one or more critical structures or organs protected by the use of Proton Beam Therapy;

• The dose to control or treat the tumor cannot be delivered without exceeding the tolerance of the normal tissue;

• There is documented clinical rationale that doses generally thought to be above the level otherwise attainable with other radiation methods might improve control rates; or

• There is documented clinical rationale that higher levels of precision associated with Proton Beam Therapy compared to other radiation treatments are clinically necessary.

For the treatment of primary lesions, the intent of treatment must be curative.

For the treatment of metastatic lesions, there must be

• the expectation of a long-term benefit (greater than 2 year of life expectancy) that could not have been attained with conventional therapy; or

• the expectation of a complete eradication of the metastatic lesion that could not have been safely accomplished with conventional therapy, as evidenced by a dosimetric advantage for proton beam radiotherapy over other forms of radiation therapy (IMRT or 3-D radiation therapy). An IMRT or 3-D radiotherapy plan will need to be generated and compared to the Proton plan for target volume coverage and toxicity analysis.

The patient's record demonstrates why Proton beam radiotherapy is considered the treatment of choice for the individual patient. Specifically, the record must address the lower risk to normal tissue, the lower risk of disease recurrence, and the advantages of the treatment over IMRT or 3-dimensional conformal radiation. Dosimetric evidence of reduced normal tissue toxicity and/or improved tumor control must be maintained.

If the above provisions are met and the patient is treated in a protocol that is designed for evidence development and for future publication, it is expected that future published data will support an outcome advantage for Medicare patients for continued coverage of the specific diagnosis. The protocol in and by itself does not constitute criteria for coverage. The presence of an Institutional Review Board (IRB) review when appropriate and patient informed consent are also expected.

If the patient cannot clearly meet the criteria for coverage but desires Proton beam radiotherapy based on a marketed theoretical advantage, the claim should be billed with the appropriate modifier appended to the treatment delivery code. (See Coding Guidelines).

Summary of evidence (opening)

n/A

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2016-10-24
Current revision effective
2026-10-08
Last reviewed by the contractor
2026-09-21
MCD version
23

The contractor lists one National Coverage Determination as related: NCD 310.1 Routine Costs in Clinical Trials. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A55313 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the CGS Administrators, LLC hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L36658 cover?

In conventional external beam radiation therapy (EBRT), the targeted tissue usually receives 95-100% of the intended dose. A major limitation of EBRT is that in some situations, because critical normal tissues cannot be completely protected from the radiation, a curative dose cannot be used. The full 1,765-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L36658 apply to?

CGS Administrators, LLC applies it to Medicare claims in 2 states: KY, OH. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L36658?

The companion billing and coding article A55315 lists 430 ICD-10-CM codes in 2 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L36658?

A denial under LCD L36658 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A55315's 430 covered diagnosis codes, then file a redetermination with CGS Administrators, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.